Aline Ranzolin1, Angela Luzia Branco Pinto Duarte2, Markus Bredemeier3, Cláudio Antônio da Costa Neto2, Bruna Maria Ascoli4, Bianca Wollenhaupt-Aguiar4, Flávio Kapczinski4, Ricardo Machado Xavier5. 1. Division of Rheumatology at the Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos 2350 sala 645, 90035-003 Porto Alegre, RS, Brazil; Division of Rheumatology at the Hospital das Clínicas da Universidade Federal de Pernambuco, Prof. Moraes Rêgo, 1235, 50670-901 Recife, PE, Brazil. Electronic address: aliranzolin@hotmail.com. 2. Division of Rheumatology at the Hospital das Clínicas da Universidade Federal de Pernambuco, Prof. Moraes Rêgo, 1235, 50670-901 Recife, PE, Brazil. 3. Division of Rheumatology at the Hospital Nossa Senhora da Conceição - Grupo Hospitalar Conceição, Av. Francisco Trein, 596, room 2048, 91350-200 Porto Alegre, RS, Brazil. 4. Bipolar Disorders Program and INCT Translational Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos 2350, 90035-003 Porto Alegre, RS, Brazil. 5. Division of Rheumatology at the Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos 2350 sala 645, 90035-003 Porto Alegre, RS, Brazil.
Abstract
OBJECTIVES: Previous studies measuring serum levels of biomarkers of inflammation/oxidative stress and neurotrophins levels in fibromyalgia (FM) have rendered inconsistent results. In the present study, our aim was to explore the levels of interleukins, oxidative stress markers and brain-derived neurotrophic factor (BDNF) in patients with FM in relation to depression and severity of disease. METHODS: In a prospective controlled cross-sectional study, serum concentrations of IL-6, IL-8, IL-10, TNF-α, thiobarbituric acid reactive substances (TBARS), protein carbonyl and BDNF were measured in 69 FM patients and 61 healthy controls (all women). In the FM group, the Fibromyalgia Impact Questionnaire (FIQ), the Beck Depression Inventory (BDI) and the Hamilton Depression Rating Scale (HDRS) were applied. Mann Whitney's and Spearman correlation tests were used for statistical analysis. RESULTS: The FM patients demonstrated a significant impact of the disease on quality of life (FIQ 70.2±17.8) and most of them had depression at some level (82.6% and 87.0% as assessed by BDI and HDRS, respectively). Most biomarkers (IL-6, IL-8, TNF-α, TBARS and protein carbonyl) and BDNF did not differ significantly between patients and controls, but the IL-10 levels were higher in FM patients (adjusted p=0.041). Among FM patients, there was no correlation of HDRS, FIQ, and BDI scores with any biomarker tested here. CONCLUSION: We observed no significant differences in biomarkers between FM patients and controls, except for higher levels of IL-10 (an anti-inflammatory cytokine) in patients. The levels of biomarkers were not correlated with parameters of disease and depression severity.
OBJECTIVES: Previous studies measuring serum levels of biomarkers of inflammation/oxidative stress and neurotrophins levels in fibromyalgia (FM) have rendered inconsistent results. In the present study, our aim was to explore the levels of interleukins, oxidative stress markers and brain-derived neurotrophic factor (BDNF) in patients with FM in relation to depression and severity of disease. METHODS: In a prospective controlled cross-sectional study, serum concentrations of IL-6, IL-8, IL-10, TNF-α, thiobarbituric acid reactive substances (TBARS), protein carbonyl and BDNF were measured in 69 FM patients and 61 healthy controls (all women). In the FM group, the Fibromyalgia Impact Questionnaire (FIQ), the Beck Depression Inventory (BDI) and the Hamilton Depression Rating Scale (HDRS) were applied. Mann Whitney's and Spearman correlation tests were used for statistical analysis. RESULTS: The FM patients demonstrated a significant impact of the disease on quality of life (FIQ 70.2±17.8) and most of them had depression at some level (82.6% and 87.0% as assessed by BDI and HDRS, respectively). Most biomarkers (IL-6, IL-8, TNF-α, TBARS and protein carbonyl) and BDNF did not differ significantly between patients and controls, but the IL-10 levels were higher in FM patients (adjusted p=0.041). Among FM patients, there was no correlation of HDRS, FIQ, and BDI scores with any biomarker tested here. CONCLUSION: We observed no significant differences in biomarkers between FM patients and controls, except for higher levels of IL-10 (an anti-inflammatory cytokine) in patients. The levels of biomarkers were not correlated with parameters of disease and depression severity.
Authors: V G C Ribeiro; V A Mendonça; A L C Souza; S F Fonseca; A C R Camargos; V K S Lage; C D C Neves; J M Santos; L A C Teixeira; E L M Vieira; A L Teixeira Junior; B Mezêncio; J S C Fernandes; H R Leite; J R Poortmans; A C R Lacerda Journal: Braz J Med Biol Res Date: 2018-03-01 Impact factor: 2.590
Authors: M Ernberg; N Christidis; B Ghafouri; I Bileviciute-Ljungar; M Löfgren; J Bjersing; A Palstam; A Larsson; K Mannerkorpi; B Gerdle; E Kosek Journal: Mediators Inflamm Date: 2018-04-18 Impact factor: 4.711